Department of Cell and Cancer Biology

Maurice Manning, Ph.D., D.Sc.

Department of Cell and Cancer Biology
Ombudsman, The University of Toledo College of Medicine and Life Sciences
maurice.manning@utoledo.edu
Curriculum Vitae 
List of Scientists Who Have Received Peptides as Research Tools 1980-2023

EDUCATION:

B.Sc.	1957	Chemistry	University College of Galway*, Galway, Ireland
M.Sc.	1958	Chemistry	University College of Galway*, Galway, Ireland
Ph.D.	1961	Organic Chemistry	University of London, London, England
D.Sc.	1974	Peptide Chemistry	University College of Galway*, Galway, Ireland

*Now The National University of Ireland, Galway (NUIG)

RESEARCH INTERESTS:

Research in my laboratory focused on the design and solid phase synthesis of peptide ligands for the vasopressin V_1a, V_1b and V₂ receptors and for the oxytocin (OT) receptor (selective agonists and antagonists; radioiodinated and fluorescent ligands).  Many of these peptides have been utilized as research tools in laboratories worldwide and have helped to advance research in the oxytocin vasopressin field. To date, over 3,000 samples of oxytocin and vasopressin agonists and antagonists from this laboratory have been donated to over 740 scientific investigators (some multiple times) for their own independent studies (see list above). Over 2,000 publications from other laboratories have resulted from the use of these peptides over the past 30 years.  I continue to supply other scientists in the U.S. and throughout the world with samples of vasopressin and oxytocin peptide agonists, antagonists and radioiodinateable ligands for their own independent studies.

Currently these peptide designs are focused on the CNS actions of oxytocin and vasopressin; with the following goals in mind:  (1) the design of (a) long-acting oxytocin agonists, (b) fluorescent oxytocin agonists, and (c) "biased" oxytocin agonists; for use as pharmacological tools and as potential therapeutic agents for the study of and treatment of autism spectrum disorders (ASD) and related disorders and (2) the design of selective antagonists, radiolabelled and fluorescent ligands for the human and rat vasopressin V_1b receptors; for studies on V_1b receptors in the brain and as potential new therapies for anxiety and stress.  The synthetic studies have been carried out in my laboratory by returning visiting scholars from Poland:  Drs. Krzysztof Bankowski, Aleksandra Olma and Aleksandra Misicka, and Bulgaria: Dr. Stoytcho Stoev.  All have made important contributions to my laboratory in the past.  The resultant peptides, are being pharmacologically characterized by long time collaborators Drs. Gilles Guillon, Maithe Corbani, Thierry Durroux and Bernard Mouillac, Montpellier, France; and by Drs. Bice Chini and Marta Busnelli, Milan, Italy.

REPRESENTATIVE PUBLICATIONS:

S. Derick, L.L. Cheng, M.J. Voirol, S. Stoev, M. Giacomini, N.C. Wo, H.H. Szeto, M. Ben Mimoun, M. Andres, R.C. Gaillard, G. Guillon and M. Manning (2002) [1-Deamino-4-Cyclohexylalanine] Arginine Vasopressin: A Potent and Specific Agonist for Vasopressin V_1b Receptors. Endocrinology 143:4655-4664.

A. Pena, B. Murat, M. Trueba, M.A. Ventura, G. Bertrand, L.L. Cheng, S. Stoev, H.H. Szeto, N. Wo, G. Brossard, C. Serradeil-Le Gal, M. Manning and G. Guillon (2007) Pharmacological and Physiological Characterization of d[Leu4,Lys8]Vasopressin, the First V1b Selective Agonist for Rat Vasopressin/Oxytocin Receptors.  Endocrinology 148:4136-4146.

M. Manning (2008) Impact of the Merrifield Solid Phase Method on the Design and Synthesis of Selective Agonists and Antagonists of Oxytocin and Vasopressin:  A Historical Perspective.  Biopolymers (Peptide Science) 90(3):203-212.

B. Chini and M. Manning (2007) Agonist Selectivity in the Oxytocin/Vasopressin Receptor Family:  New Insights and Challenges.  Biochem. Soc. Transactions 35 (Pt4):737-741.

M. Manning, S. Stoev, B. Chini, T. Durroux, B. Mouillac and G. Guillon (2008) Peptide and Nonpeptide Agonists and Antagonists for the Vasopressin and Oxytocin V_1a, V_1b, V₂ and OT Receptors:  Research Tools and Potential Therapeutic Agents.  In Advances in Vasopressin and Oxytocin - from Genes to Behaviour and Disease (eds. Rainer Landgraf and Inga Neumann) Prog. Brain Res. 170:473-512.

M. Manning.  Peptides versus Non-Peptides.  Invited commentary in The European Peptide Society Newsletter (Ed. Paul Cordopatis).  European Peptide Society:  Issue Number 41: 14, January 2010.  Reprinted in American Peptide Society Newsletter, Spring 2010, page 5.

L. Albizu, M. Cottet, M. Kralikova, S. Stoev, R. Seyer, I. Brabet, T. Roux, H. Bazin, E. Bourrier, L. Lamarque, C. Breton, M.-L. Rives, A.H. Newman, J.A. Javitch, E. Trinquet, M. Manning, J.-P. Pin, B. Mouillac and T. Durroux (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.  Nature Chem. Biol. 6:587-594.

B. Mouillac, M. Manning and T. Durroux. (2008) Fluorescent agonists and antagonists for vasopressin/oxytocin G-protein-coupled receptors: usefulness in ligand screening assays and receptor studies.  Mini Reviews in Medicinal Chemistry 8(10):996-1005.

M. Manning, S. Stoev and K. Bankowski.  Peptides Versus Non-Peptides as Therapeutics: An Exciting Challenge for Big Pharma. Proceedings of the 31^st European Peptide Symposium (M. Lebl, M. Mendal, K.J. Jensen, T. Hoeg-Jensen (eds.).  European Peptide Society, 366-367, 2010.

M. Corbani, M. Trueba, S. Stoev, B. Murat, J. Mion, V. Boulay, G. Guillon and M. Manning (2011) Design, Synthesis and Pharmacological Characterization of Fluorescent Peptides for Imaging Human V_1b Vasopressin or Oxytocin Receptors.  J. Med. Chem. 54:2864-2877.

M. Manning, A. Misicka, A. Olma, K. Bankowski, S. Stoev, B. Chini, T. Durroux, B. Mouillac, M. Corbani and G. Guillon (2012) Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics.  J. Neuroendocrinology 24:609-628.  (Most highly cited J.N.E. publication in 2015)

M. Busnelli, E. Bulgheroni, M. Manning, G. Kleinau and B. Chini (2013) Selective and Potent Agonists and Antagonists for Investigating the Role of Mouse Oxytocin Receptors.  Journal of Pharmacology and Experimental Therapeutics.  346:318-327.

M. Busnelli, G. Kleinau, M. Mutenthaler, S. Stoev, M. Manning, L. Bibic, L.A. Howell, P.J. McCormick, S. Di Lascio, D. Braida, M. Sala, G.E. Rovati, T. Bellini and B. Chini (2016) Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure. J. Med. Chem. 59:7152-7166.  (ACS Editor's Choice of July 28, 2016)

M. Corbani, R. Marir, M. Trueba, M. Chafai, A. Vincent, A.M. Borie, M.J. Desarmenien, Y. Ueta, C. Tomboly, A. Olma, M. Manning, G. Guillon (2018) Neuroanatomical distribution and function of the vasopressin V_1B receptor in the rat brain deciphered using specific fluorescent ligands. Gen. Compar. Endocrinol. 258:15-32.